Corticosterone
|
Basic information |
| Metabolite name | Corticosterone |
 | HMDB0001547 |
 |
C02140 |
 |
5753 |
| Synonyms | NA |
| No. of studies | 23 |
|
Basic information |
| Metabolite name | Corticosterone |
| HMDB0001547 |
|
C02140 |
|
5753 |
| Synonyms | NA |
| No. of studies | 23 |
|
Relationship between Corticosterone and depression (count: 23) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M096 | Type1 | CUMS group vs. control group | Plasma | Wistar rat | Up |
| Study M1024 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M1097 | Type1 | placebo-treated depression group vs. control group | Faece | Human | Down |
| Study M1098 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1098 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1125 | Type1 | CRS group vs. control group | Plasma | c57BL/6J mouse | Up |
| Study M1125 | Type2 | CRS + siSMAPoTN group vs. CRS group | Plasma | c57BL/6J mouse | Down |
| Study M1138 | Type1 | unpredictable subchronic stress group vs. control group | Hippocampus | Swiss mouse | Up |
| Study M1138 | Type2 | unpredictable subchronic stress + imipramine group vs. unpredictable subchronic stress group | Hippocampus | Swiss mouse | Down |
| Study M137 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M137 | Type2 | CUMS + hypericin group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M137 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M161 | Type1 | CMS group vs. control group | Plasma | Mouse | Up |
| Study M166 | Type1 | LPS group vs. control group | Plasma | Wistar rat | Up |
| Study M166 | Type2 | LPS + high dose of Rg1 group vs. LPS group | Plasma | Wistar rat | Down |
| Study M166 | Type2 | LPS + minocycline group vs. LPS group | Plasma | Wistar rat | Down |
| Study M166 | Type2 | LPS + low dose of Rg1 group vs. LPS group | Plasma | Wistar rat | Down |
| Study M503 | Type1 | SDS group vs. control group | Plasma | Wistar Kyoto rat | Up |
| Study M503 | Type2 | SDS + URB694 group vs. SDS group | Plasma | Wistar Kyoto rat | Down |
| Study M532 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M575 | Type1 | CUMS group vs. control group | Serum | Wistar rat | Up |
| Study M606 | Type1 | CUMS group vs. control group | Hair | Wistar rat | Down |
| Study M606 | Type2 | CUMS + cannabidiol group vs. CUMS group | Hair | Wistar rat | Up |
| Study M689 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M689 | Type2 | CUMS + Danzhi Xiaoyao Powder group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M691 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M691 | Type2 | CUMS + low dose of Chaihu group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M691 | Type2 | CUMS + low dose of Baishao group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M691 | Type2 | CUMS + low dose of Chaihu-Baishao group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M697 | Type1 | social isolation group vs. control group | Plasma | Groningen rat | Up |
| Study M697 | Type2 | social isolation + URB694 group vs. social isolation group | Plasma | Groningen rat | Down |
| Study M704 | Type3 | low dose of sertraline group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M704 | Type3 | middle dose of sertraline group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M704 | Type3 | low dose of sertraline group vs. control group | Adrenal gland | Sprague-Dawley rat | Down |
| Study M704 | Type3 | middle dose of sertraline group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M704 | Type3 | high dose of sertraline group vs. control group | Adrenal gland | Sprague-Dawley rat | Down |
| Study M704 | Type3 | low dose of sertraline group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M704 | Type3 | low dose of sertraline group vs. control group | Testis | Sprague-Dawley rat | Down |
| Study M704 | Type3 | high dose of sertraline group vs. control group | Testis | Sprague-Dawley rat | Down |
| Study M704 | Type3 | high dose of sertraline group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M704 | Type3 | high dose of sertraline group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M704 | Type3 | middle dose of sertraline group vs. control group | Testis | Sprague-Dawley rat | Down |
| Study M704 | Type3 | middle dose of sertraline group vs. control group | Adrenal gland | Sprague-Dawley rat | Down |
| Study M744 | Type1 | CUS transplant group vs. control transplant group | Hippocampus | Sprague-Dawley rat | Down |
| Study M802 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M802 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M850 | Type1 | reserpine group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M945 | Type1 | MDD group vs. control group | Serum | Human | Up |
| Study M957 | Type1 | CSDS group vs. control group | Serum | C57BL/6 J mouse | Up |